^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MSI-H/dMMR + POLE mutation

    i
    Other names: MSI-H, Microsatellite instability - high, dMMR, POLE1, DNA Polymerase Epsilon Catalytic Subunit, DNA Polymerase Epsilon Catalytic Subunit A, Polymerase (DNA) Epsilon Catalytic Subunit, DNA Polymerase II Subunit A, Polymerase (DNA Directed) Epsilon Catalytic Subunit, DNA Polymerase Epsilon Catalytic Subunit Protein, Polymerase (DNA Directed) Epsilon
    Entrez ID:
    5426
    Related biomarkers:
    Expression
    Mutation
    Others
    over1year
    A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images. (ASCO 2023)
    A CLAM-based deep learning model could directly predict the MSI-H and POLE mutation from histological images that could be used to stratify CRC patients for immunotherapy with faster turnaround time and lower costs compared with traditional sequencing methods.
    Tumor mutational burden • Microsatellite instability • MSi-H Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)
    |
    MSI-H/dMMR • POLE mutation • TMB-L • MSI-H/dMMR + POLE mutation
    over2years
    Phase II study of durvalumab monotherapy in patients with previously treated microsatellite instability-high/mismatch repair-deficient or POLE-mutated metastatic or unresectable colorectal cancer. (PubMed, Int J Cancer)
    In conclusion, durvalumab showed promising clinical activity with encouraging response rates and satisfactory survival outcomes in mCRC patients with MSI-H/dMMR or POLE EDM. In patients with POLE-mutated mCRC, clinical response to durvalumab may be restricted to those with EDM.
    P2 data • Clinical Trial,Phase II • Journal • Mismatch repair • Microsatellite instability • MSi-H Biomarker • PD(L)-1 Biomarker
    |
    MSI (Microsatellite instability) • POLE (DNA Polymerase Epsilon)
    |
    MSI-H/dMMR • POLE mutation • MSI-H/dMMR + POLE mutation • POLE EDM
    |
    Imfinzi (durvalumab)